A method of treating cold hyperresponsiveness of the airways

 

(57) Abstract:

The invention relates to medicine, pulmonology and can be used to treat cold hyperresponsiveness of the Airways in patients with chronic obstructive pulmonary disease. Explore the original value of the change of forced expiratory volume in the first second (FEV1in % of initial value after bronchoprovocation samples with cold air, solve discriminant equation: D=3,465·FEV1and when the value D is greater -59,3 treatment with fenspiride in a daily dose of 160 mg for 3 months. This invention improves the efficiency of treatment with fenspiride patients at the expense of adequate, specific, and their individual reactions to this drug.

The invention relates to medicine, in particular to pulmonology and can be used to treat cold hyperresponsiveness of the Airways in patients with chronic obstructive pulmonary disease.

The prototype was elected as a method of treatment of hyperresponsiveness of the Airways in patients with chronic bronchitis by applying fenspiride [1].

The method consists in the application of fenspiride in a daily dose of 160 mg

Svea treatment fenspiride when cold hyperresponsiveness of the Airways.

2. The method does not allow one to predict the effectiveness of treatment with fenspiride hyperresponsiveness of the Airways in patients with chronic obstructive pulmonary disease.

The purpose of the invention is to improve the effectiveness of treatment with fenspiride cold hyperresponsiveness of the Airways in patients with chronic obstructive pulmonary disease, by projecting the positive therapeutic effect of fenspiride on the basis of quantitative estimation cold hyperresponsiveness of the Airways.

The objective is achieved by quantifying the cold hyperresponsiveness of the Airways is based on measuring the change of forced expiratory volume in 1 second (FEV1after bronchoprovocation samples with cold air, and the prediction is performed using the discriminant equation based on the measured value of the specified parameter.

The claimed method has the following methods:

a) using spirometry determine the value of forced expiratory volume in 1 second (FEV1), expressed in l/s;

b) a generator of cold air, for example RHES (Erich Jaeger Germany), spend the guise of FEV1expressed in l/s;

g) determine the change in FEV1(FEV1), expressed in% of initial value;

d) solve discriminant equation (L);

D=3,465·FEV1

where D is the discriminant function, a limit value which is -59,3.

The presence of positive treatment result from the use of fenspiride is projected at more -59,3, and when D is less than the boundary values of the predicted absence of positive treatment outcome.

Fenspirid used in a daily dose of 160 mg for 3 months.

Below are two examples of the use of the claimed method.

Example 1. H., 43.

Diagnosis: chronic obstructive pulmonary disease, stage I. Easy for acute stage.

Source data FEV1after isocapnic hyperventilation of cold air amounted to 17% of initial value.

In order to predict the treatment outcome of hyperreactivity respiratory tract with fenspiride resolved discriminant equation:

D=3,465·(-17)=-58,9

Because discriminant function more boundary values -59,3, expected positive results the s Laboratory Servier, France) in a daily dose of 160 mg indicator FEV1after isocapnic hyperventilation of cold air amounted to 2% of the original value, indicating the disappearance of the cold hyperreactivity respiratory tract.

Example 2. P., 49.

Diagnosis: chronic obstructive pulmonary disease, stage I. Easy for acute stage.

Source data FEV1after isocapnic hyperventilation of cold air was up 31% from the original value.

In order to predict the treatment outcome of hyperreactivity respiratory tract with fenspiride resolved discriminant equation:

D= 3,465·(-31)=-107,4

Since the discriminant function is less than the boundary values -59,3, predicted the absence of a positive effect of treatment with fenspiride on the disappearance of the cold hyperresponsiveness of the Airways.

After 3 months of treatment with fenspiride in a daily dose of 160 mg indicator FEV1after isocapnic hyperventilation of cold air amounted to 19% of the original value, indicating that the preservation of the cold hyperreactivity respiratory tract.

The proposed method was KLINICHESKOI respiration SB RAMS. Using a forecasting method of treatment effectiveness cold hyperreactivity respiratory tract with fenspiride in 24 patients with chronic obstructive pulmonary disease.

The results of the verification of the claimed method has shown its effectiveness. A correct prediction is determined in 80% of cases.

Thus, the proposed method can be effectively used for predicting treatment of cold hyperreactivity respiratory tract with fenspiride in patients with chronic obstructive pulmonary disease.

The list of references

1. Fisenko B. N. Pharmacology of erasala // Doctor, 2001, 5 - N-35.

A method of treating cold hyperresponsiveness of the Airways in patients with chronic obstructive pulmonary disease, including the use of fenspiride, wherein investigate the source value changes of forced expiratory volume in the first second (FEV1in % of initial value after bronchoprovocation samples with cold air, solve discriminant equation

D=3,465·FEV1

and when the value D is greater -59,3 treatment with fenspiride in a daily dose of 160 mg for 3 months.



 

Same patents:
The invention relates to medicine, in particular to urology and endocrinology

The invention relates to new arylpiperazine derivative of General formula I

< / BR>
and their pharmaceutically acceptable salts, esters, where Y is O; Q is CH; X, Z and Z' each independently represent CH or N; m=0-1; n=0-4; R1and R2independently selected from H, F, Cl, Br, OCH3OC2H5, OCH2CF3CH3WITH2H5, CF3isopropylate; R3represents H; R4and R5represent H or phenyl, except that R1represents H, R2represents H, Cl or CF3, R3, R4and R5=N, Y=0, and Q=CH, if m=0 and n=1; and also except that R1represents H, R2is OCH3, R3, R4and R5=H, Y=0, Q=CH, if m=0 and n=2

The invention relates to medicine, in particular to urology, and for the treatment of prostate tumors
The invention relates to medicine, in particular to urology, and for the treatment of BPH
The invention relates to medicine, in particular to surgery, and can be used for the treatment of chronic prostatitis

The invention relates to medicine, in particular to drugs on the basis of finasteride, which is an inhibitor of 5-reductase
The invention relates to medicine

The invention relates to new guanidinium heterocyclic compounds of the formula (I), where R1denotes H, alkyl or is absent when R1missing link (a) is a double bond, D represents CR2, R2selected from H, alkyl, halogen, or, when is a CR3D can be N, denotes NR9, CR3=CR8, CR3, S, where R9denotes H, alkyl, alkenyl or quinil and where R3and R8selected from H, alkyl, alkenyl, quinil or cyano, R4, R5, R6each independently selected from H, alkyl, alkenyl, quinil, cyano, halogen or NH-C(= NR10)OTHER11(guanidine), R10and R11selected from H, methyl and ethyl, and where only one of R1, R5and R6is guanidines, R7selected from H, alkyl, alkenyl, quinil and halogen

The invention relates to medicine and can be used for the treatment of diseases of urogenital organs, mainly the prostate

The invention relates to compounds of formula (1), where X and Y Is N or O; R1substituted alkyl, substituted arylalkyl or cycloalkyl; R2and R3Is h or alkyl; And a Is-C(O)-, -OC(O)-, -S(O)2-; R4- alkyl, cycloalkyl or (C5-C12)aryl; compounds of the formula (2), where X and Y are O, S or N; R1- alkyl, optionally substituted arylalkyl; R2and R3Is h or alkyl;- C(O)-; R6- Deputy, including the condensed heterocyclic rings; and compounds of the formula (3), where X and Y are O, S or N; R1- alkyl, alkylsilane, (C5-C12)arylalkyl, (C5-C12)aryl; R2and R3Is h or alkyl; R2' and R3' - N; R11, R12and E together form a mono - or bicyclic ring which may contain heteroatoms

The invention relates to a derivative of 1,2,4-thiadiazole, substituted in the 5-position of General formula I, in which X Is N; R1- C1-6alkyl; R2is hydrogen, R3, R4and R5each independently selected from hydrogen; trifloromethyl;is Ar2, Ar2CH2or Het2; AG2is phenyl; Het2is a monocyclic heterocycle selected from thiadiazolyl, pyridinyl, pyrimidinyl or pyrazinyl, their N-oxide forms, the pharmaceutically acceptable acid additive salts and stereochemical isomeric forms

The invention relates to medicine, specifically to pharmacology

The invention relates to new derivatives of 2-(1,2,4-triazole-1-yl)-1,3,4-thiadiazole of the formula I, in which R1means a hydrogen atom, a C1-4alkyl group or phenyl group which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy-group, nitro group, WITH1-4alkoxygroup, (C1-4alkyl) amino and di(C1-4alkyl)amino group; or a group of formula (a) Z means a hydrogen atom or a C1-4alkoxygroup, R0means a group of the formula Alk-NR4R5where Alk is alkalinous group having a straight or branched C1-6chain, one of R2and R3is amino and the other is an amino group or a 5-6-membered saturated heterocyclic group containing one or two atom(s) of nitrogen and/or oxygen and attached via its nitrogen atom, and the specified heterocyclic group may be substituted WITH1-4alkyl group, phenyl group or kalogeropoulou group, or the last of the R2and R3is a group of the formula - SR

The invention relates to derivatives of 2,1,3 - benzothiadiazole General formula I, where the R group of formula I', X Is S; R' is H, OH, OA, where A is alkyl with 1-6 C-atoms, in which 1-7 h atoms may be replaced by F

The invention relates to a medicinal product on the basis of derivatives of thiazole or thiadiazole of the formula I, where a denotes a linear or branched C1-C18-alkylenes group which may contain at least one group selected from the group consisting of: O, S, NR3, СОNR3, NR3CO, COO, OCO or double or triple bond; In denotes the radical of the formula II, R1denotes H, halogen JV CO2R2, NR2R3, OR SIG3, CF3or C1-C8-alkyl, which is unsubstituted or substituted HE OS1-C8-alkyl or halogen; R2denotes H, C1-C8-alkyl, which is unsubstituted or substituted HE OS1-C8-alkyl or halogen, or phenyl-C1-C8-alkyl; R3has the meanings given for R2or indicate СОR2or CO2R2; X represents N or CR4where R4denotes H, C1-C8-alkyl, which is not substituted or is substituted by IT, OS1-C8-alkyl or halogen, or denotes phenyl which is not substituted or substituted with halogen, CF3C1-C8-alkyl or C1-C8-alkoxy; Ar denotes phenyl, pyridyl, pyrimidyl or triazinyl,

The invention relates to compounds of formula (I):

< / BR>
where

-A= B-C= D - represents-CH=CH-CH=CH-group, in which 1 or 2 CH may be replaced by nitrogen;

Ar denotes phenyl or naphthyl, unsubstituted or one-, two - or three-fold substituted with H, Gal, Q, alkenyl with the number of C-atoms up to 6, Ph, OPh, NO2, NR4R5, NHCOR4, CF3, OCF3CN, OR4, COOR4, (CH2)nCOOR4, (CH2)nNR4R5, -N=C=O or NHCONR4R5phenyl or naphthyl;

R1, R2, R3each independently from each other, are absent or represent H, Gal, Q, CF3, NO2, NR4R5, CN, COOR4or CHCOR4;

R4, R5each independently of one another denote H or Q, or together also denote-CH2-(CH2)N-CH2-;

Q denotes alkyl with 1-6 C-atoms;

Ph denotes phenyl;

X denotes O or S;

Gal denotes F, Cl, Br or I;

"n" represents 1, 2 or 3;

and their salts, except 4-methyl-N-(2,1,3-benzothiadiazole - 5-yl)benzosulfimide, 4-nitro-N-(2,1,3-benzothiadiazole-5-yl)- benzosulfimide and 4-amino-N-(2,1,3-benzothiadiazole-5-yl)- benzolsulfonat

The invention relates to therapeutic active usacycling or azabicyclic compounds, method of their preparation and to pharmaceutical compositions comprising these compounds
The invention relates to the field of veterinary medicine

The invention relates to medicine, in particular to neurosurgery, and can be used for the diagnosis of brain edema is at its focal lesions
Up!